LYMPHOMAS

Kami Maddocks, MD, presents the patient diagnosis and treatment history of a 74-year-old-man with relapsed/refractory follicular lymphoma.

Kami Maddocks, MD, reviews the case of a 74-year-old man with relapsed/refractory follicular lymphoma and discusses current treatment options.

Anthony Mato, MD, MSCE, discusses the use of a triplet combination of the novel Bruton tyrosine kinase inhibitor DTRMWXHS-12, the mTOR inhibitor, everolimus, and the IMiD pomalidomide for the treatment of relapsed/refractory Richter’s transformation and de novo diffuse large B-cell lymphoma.

Dr Lunning reviews potential options for later line therapy for patients with R/R DLBCL and shares his thought about future directions in the evolving treatment landscape.

Matthew Lunning, DO, presents the efficacy and safety findings of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma and discusses the implications for clinical practice.

Dr Matthew Lunning reviews second-line treatment options for patients with R/R DLBCL and provides insight on individualizing therapy.

DLBCL expert Matthew Lunning, DO, describes risk assessment in patients with DLBCL and how it informs first-line treatment choice.

Matthew Lunning, DO, presents a case of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma and discusses considerations for therapy.

Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.

Pirtobrutinib showed promising efficacy and safety as treatment of patients with mantle cell lymphoma, demonstrating the potential to serve an unmet medical need.

The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.

Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.

In relapsed and untreated patients with mantle cell lymphoma, the combination of obinutuzumab, ibrutinib, and venetoclax achieved molecular response rates and was found to be well tolerated, results from the phase 1/2 OAsIs trial demonstrate.

Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.

Alex F. Herrera, MD, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed or refractory Hodgkin lymphoma.

For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.

Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.